rotavirus vaccine, live, oral

(ro-ta-vye-russ vak-seen) ,


(trade name),


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: active immunizer
Pregnancy Category: C


Prevention of rotavirus gastroenteritis in infants.


Live attenuated vaccine replicates in the small intestine and produces immunity.

Therapeutic effects

Prevention of rotavirus gastroenteritis and its sequelae.


Absorption: Unknown.
Distribution: Remains in GI tract.
Metabolism and Excretion: Excreted in feces.
Half-life: Unknown.

Time/action profile



Contraindicated in: Hypersensitivity; History of intussusception; Severe combined immunodeficiency disease.
Use Cautiously in: Acute diarrhea or vomiting (delay immunization); Chronic gastrointestinal disorders (safety and efficacy not established); Febrile illness; Immunosuppression due to disease (including HIV), concurrent immunosuppressive drug therapy, malignant neoplasms affecting bone marrow/lymphatic system, or receipt of blood transfusion or blood products (including immunoglobulins) (safety and effectiveness not established).

Adverse Reactions/Side Effects


  • cough

Ear, Eye, Nose, Throat

  • runny nose


  • Intussusception (life-threatening)
  • flatulence
  • loss of appetite
  • rotavirus shedding in stool
  • vomiting


  • fussiness/irritability


Drug-Drug interaction

Concurrent immunosuppressants, antineoplastics, corticosteroids or radiation therapy may ↓ antibody response and ↑ risk of adverse reactions.



Oral (Infants 6–24 wk) 2 dose series; first dose at 6 weeks of age, followed at least 4 weeks later with a second dose; series should be completed by 24 weeks of age.


Oral (Infants 6–32wk) 3 dose series; first dose at 6–12 weeks of age, followed by the 2nd and 3rd doses at 4–10 week intervals; series should be completed by 32 weeks of age.


Powder for oral suspension (Rotarix) (requires reconstitution): 1 mL prefilled oral applicator (applicator contains latex)
Oral solution (Rotateq): 2 mL prefilled dosing tube

Nursing implications

Nursing assessment

  • Determine current health status and previous vaccination history of infant, including any reactions to previous dose of rotavirus vaccine. Delay administration in infants with acute diarrhea and vomiting.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • May be administered with food or liquid, including breast milk, either before or after vaccination.
  • Oral: For Rotarix: Remove vial cap and push transfer adaptor into vial. Shake diluent in oral applicator (white, turbid suspension); push plunger of oral applicator to transfer diluent into vial. Reconstitute only with accompanying diluent. Do not mix with other vaccines or solutions. Do not administer if vial has cracks. Withdraw vaccine in oral applicator and twist to remove oral applicator. Do not use a needle; not for injection Vials of vaccine may be stored in the refrigerator and diluent may be stored at room temperature. Do not freeze. Administer within 24 hr of reconstitution. Discard in biological waste container if not used within 24 hrs.
    • If infant spits out or regurgitates most of dose, single replacement dose may be considered at same vaccination visit.
  • For RotaTeq: Open the dosing tube and puncture dispensing tip by screwing cap clockwise until it becomes tight. Administer dose by gently squeezing liquid into infant's mouth toward the inner cheek until dosing tube is empty. A residual drop may remain in the tip of the tube.
    • If infant spits out or regurgitates most of dose, a replacement dose is not recommended. The infant should continue to receive any remaining doses in the recommended series.

Patient/Family Teaching

  • Instruct parents or guardians to read Patient Information before first dose and prior to second dose and ask any questions they may have during the visit. Provide parent or guardian with the Vaccine Information Statements available at Emphasize the importance of completing the immunization series.
  • Advise parent to contact health care professional immediately if signs of intussusception (vomiting, diarrhea, severe stomach pain, severe crying, blood in the stool, or change in bowel movements) occur even if it has been several months since last vaccine dose.

Evaluation/Desired Outcomes

  • Prevention of rotavirus gastroenteritis and its sequelae.




Human live, oral rotavirus vaccine, monovalent.
References in periodicals archive ?
In 2006 and 2008, two live-attenuated vaccines, RotaTeq (Merck, Whitehouse Station, NJ, USA) and Rotarix (GlaxoSmithKline, Rixensart, Belgium), respectively, were introduced in the United States (4).
Two rotavirus vaccines, Rotarix (GSK Biologicals) and Rotateq (Merck & Co) have been licensed since 2006 and are used in both Western and developing world countries.
Dr Peter Basile, Medical Manager for vaccines at GSK, which manufactures the rotavirus vaccine, Rotarix, said: 'These figures are fantastic news.
This incremental growth has been due to blockbuster vaccines (Prevnar7, Prevnar 13, Rotarix and Rotateq) sales in Billion of US$ which made a significant contribution.
Rotavirus vaccines are currently available in oral drops of two or three doses, and costs from Dh255 per dose for Rotarix (two doses) and Dh273 per dose for RotaTeq (three doses).
The company said it had received approval from US regulators for its epilepsy drug Potiga, European approval for the Benlysta drug for lupus and approval for use of Rotarix for the prevention of rotavirus in Japan.
GlaxoSmithKline noted that Potiga, for epilepsy, Benlysta, for lupus, together with Rotarix, for rotavirus, have been approved for use by FDA.
Rotarix In March, the FDA asked pediatricians to stop administering Rotarix, a vaccine made by GlaxoSmithKline that prevents rotavirus infection, a diarrheal illness that can cause severe dehydration.
The company sells vaccines such as Rotarix for rotaviral diarrhea and Cervarix for the prevention of cervical cancer.
Increased generic competition and the temporary suspension of its Rotarix vaccine hit business in the US, although the fall was offset by emerging markets and Japan as well as pounds 275m in sales of the pandemic H1N1 vaccine.
PESHAWAR, May 22 -- The US Food and Drug Administration (FDA) on May 14 revised its recommendations for rotavirus vaccines for the prevention of the disease in infants and determined that it was appropriate for healthcare professionals to resume the use of Rotarix and to continue the use of RotaTeq, says a press release issued on Friday.
London, Jan 28 (ANI): Rotavirus vaccine, Rotarix, could effectively reduce the overall incidence of severe rotavirus diarrhoea in developing countries, finds a new study.